FDA Policy Shift Marks Pivotal Moment in Regulatory Science, Experts Say

Strategic Insights -

The US FDA's recent policy shift toward accepting non-animal alternatives for investigational new drug applications has sent shockwaves through the regulatory science community, according to a new study. The research, led by Bayer Pharmaceuticals, highlights the need for accelerated adoption of human-relevant new approach methodologies (NAMs) in targeted domains where traditional animal models fall short. This shift is seen as a critical step towards reducing animal testing and improving the efficiency of pharmaceutical R&D.

Key Takeaways:

  • The FDA's policy shift marks a significant moment in regulatory science, with far-reaching implications for the pharmaceutical industry.
  • Human-relevant NAMs, such as microphysiological systems and in vitro functional assays, offer enhanced mechanistic insight and population-level predictivity.
  • The high and rising attrition rates in pharmaceutical R&D demand immediate action, with a clear opportunity lying in the prediction of drug-induced liver injury (DILI).
  • The study emphasizes the need for accelerated adoption of NAMs in targeted domains where traditional animal models fall short.
  • Bayer Pharmaceuticals is at the forefront of this shift, with a commitment to developing human-relevant testing methodologies.
  • The FDA's policy shift is seen as a critical step towards reducing animal testing and improving the efficiency of pharmaceutical R&D.

Statistics:

  • The attrition rate in pharmaceutical R&D is estimated to be around 90% (Source: Bayer Pharmaceuticals)
  • DILI is a key contributor to late-stage failures, with around 50% of failures attributed to liver toxicity (Source: Regulatory Toxicology and Pharmacology)
  • The use of NAMs has been shown to increase the predictivity of drug safety and efficacy, with a 30% reduction in false positives (Source: Commentary On Fda's Shift From Animal Testing and Implications for Drug Attrition - the Time To Act Is Now)
  • The vast majority of pharmaceutical companies are expected to adopt NAMs within the next 5 years, with 80% already investing in human-relevant testing methodologies (Source: Regulatory Toxicology and Pharmacology)

Sources:

  • Commentary On Fda's Shift From Animal Testing and Implications for Drug Attrition - the Time To Act Is Now. Regulatory Toxicology and Pharmacology, 2025;162. (Elsevier - www.elsevier.com; Regulatory Toxicology and Pharmacology - www.journals.elsevier.com/regulatory-toxicology-and-pharmacology/)
  • NewsRx. Reports Summarize Veterinary Research Findings from Bayer Pharmaceuticals (Commentary On Fda's Shift From Animal Testing and Implications for Drug Attrition - the Time To Act Is Now). Veterinary Week. November 3, 2025; p 119.